Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.
Tiago TorresAndrea ChiricozziLuis PuigAna Maria LéAngelo Valerio MarzanoPaolo DapavoEsteban DaudenJόse-Manuel CarrascosaElizabeth LazaridouGleison DuarteAndré V E CarvalhoRicardo RomitiNatalia RompotiLaetitia TeixeiraMiguel AbreuElena IppolitiCarlo Alberto MaroneseMar Llamas-VelascoEva VilarrasaElena Del AlcázarAthina-Ioanna DaponteMarina PapoutsakiAndrea CarugnoFrancesco BellinatoPaolo GisondiPublished in: American journal of clinical dermatology (2024)
The risk of tuberculosis reactivation in patients with psoriasis and LTBI does not seem to increase with IL-17 or IL-23 inhibitors. IL-17 or IL-23 inhibitors should be preferred over TNF antagonists when concerns regarding tuberculosis reactivation exists. In patients with LTBI considered at high risk for developing complications related to chemoprophylaxis, this preventive strategy may be waived before initiating treatment with IL-17 inhibitors and especially IL-23 inhibitors.